NASDAQ:DFNT 18 April 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.

18 April 2026

Biotechnology·NASDAQ:DFNT·Pharmaceutical Industry

Goldman Sachs Stock Valuation After 50% Yearly Gain: Overvalued or Time to Pause?
June 28, 2026, 4:07 AM EDT. Goldman Sachs Group's (GS) stock closed at $1,019.61, down 7% in the last week but up 50.6% over the past year. Despite strong multi-year gains-239.1% over three years-the stock shows a recent pullback. Valuation analysis using an Excess Returns model suggests the stock is about 10.4% overvalued, with an intrinsic value estimate of $923.45 per share versus the current price. The company's Price-to-Earnings (P/E) ratio remains a key metric for assessing investor expectations relative to earnings. This price-behavior mix invites investors to carefully weigh valuation models against robust historical returns and shifting market conditions before considering new positions.

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026

LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 4:10 AM EDT Goldman Sachs Stock Valuation After 50% Yearly Gain: Overvalued or Time to Pause? June 28, 2026, 4:07 AM EDT. Goldman Sachs Group’s (GS) stock closed at $1,019.61, down 7% in the last week but up 50.6% over the past year. Despite strong multi-year gains-239.1% over three years-the stock shows a recent pullback. Valuation analysis using an Excess Returns model suggests the stock is about 10.4% overvalued, with an intrinsic value estimate of $923.45 per share versus the current price. The company’s Price-to-Earnings (P/E) ratio remains

Bank of America (NYSE:BAC) trades near highs as Fed stress test details leave investors watching payout schedule

28 June 2026

Bank of America (NYSE:BAC) closed at $57.88, down 0.53% after hitting a 52-week high, as investors await a July board decision on the next dividend following a Fed stress test showing commercial and industrial loans make up the largest share of projected losses, keeping focus on corporate credit ahead of July 14 earnings.

PepsiCo (NASDAQ:PEP) starts holiday week as target cuts hit defensive trade

28 June 2026

PepsiCo (NASDAQ:PEP) jumped 1.34% to $141.39 Friday but remains 17.55% below its February high as Jefferies, BofA, and Citi slashed price targets ahead of July 9 Q2 results, signaling caution even as the average analyst target sits 18.27% above the last close.

Constellation Energy (NASDAQ:CEG) closes week close to 52-week low, as nuclear renewal initiative continues

28 June 2026

Constellation Energy (CEG) shares plunged 4.2% last week, erasing $4.1 billion in value and closing near a 52-week low at $264.02, even as the company filed for New York nuclear license extensions and secured Walmart’s first nuclear power purchase agreement, with Wall Street’s average analyst target still at $362.35.

NASDAQ:DFNT 18 April 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Stock Market Today

Latest articles

US Stock Market Today: Live Updates 28.06.2026

Bank of America (NYSE:BAC) trades near highs as Fed stress test details leave investors watching payout schedule

PepsiCo (NASDAQ:PEP) starts holiday week as target cuts hit defensive trade

Constellation Energy (NASDAQ:CEG) closes week close to 52-week low, as nuclear renewal initiative continues

Latest Video